What are the side effects of Cagrilintide?

Users most often report fatigue, appetite loss, depressive episode. Side effects came up 5 times across 32 reports.

Cagrilintide side effects

Q: Is Cagrilintide safe?

Cagrilintide is not an approved supplement and carries serious risks. User reports can't establish safety. PubMed lists 9 meta-analyses and 15 randomized trials. Talk to a doctor or pharmacist, especially if you take other medication.

Across 32 first-hand reports, people mentioned a side effect 5 times (about 16 per 100 reports). The most common: fatigue, appetite loss, depressive episode. User reports show what people notice — they can't tell you whether Cagrilintide is safe for you.

High-risk compound. Not an approved supplement; serious and sometimes irreversible risks, banned in sport, may be restricted where you live.

Reported side effects

fatigue3

appetite loss1

depressive episode1

In their own words

“Every needs to be aware of the severe fatigue that shows up for some ppl, for me it almost landed me in a depressive episode.”

MixedRead the discussion ↗

“I just added Cagri .25 to my Tirz 4.0, loving the additional suppression. It does make me very tired first 12 hours after injection.”

HelpedRead the discussion ↗

“I did .25mg and couldn’t eat for 3 days. I can’t even imagine a full dose.”

MixedRead the discussion ↗

Is Cagrilintide safe? What the research covers

AResearch: Strong9 meta-analyses · 15 randomized trials on PubMed

BMJ · 2024

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

Conclusion: GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events.

BMJ · 2026

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

Conclusion: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation. Most agents do not improve quality of life meaningfully and few show cardiovascular benefits. Decisions in clinical practice should consider trade-offs between benefits and harms within the context of shared decision making.

Biomed Pharmacother · 2024

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis

Conclusion: CagrANDsema exerts the best effect for weight loss. In terms of current dose levels, a higher dose gets better weight-loss effects without increasing the risk of adverse events.